Compare Cytokinetics Inc (CYTK) vs JPMorgan Ultra Short Income ETF (JPST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs JPMorgan Ultra Short Income ETF — how do they compare? Cytokinetics Inc trades at $61.95 (market cap $8.62B), while JPMorgan Ultra Short Income ETF trades at $50.28 (market cap $42.37B). The key difference: JPMorgan Ultra Short Income ETF is far larger — about 4.9× Cytokinetics Inc's market cap, and Cytokinetics Inc is trading nearer its 52-week high, JPMorgan Ultra Short Income ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Cytokinetics Inc for 19 Days and JPMorgan Ultra Short Income ETF for 46 Days on average.
| CYTK | JPST | |
|---|---|---|
Market Cap | $8.62B | $42.37B |
Volume | 2,594,626 | 7,889,185 |
Sector | Health | Fixed Income |
52-Week High | $87.26 | $50.78 |
52-Week Low | $54.76 | $50.22 |
Typical Hold Time | 19 Days | 46 Days |
Enterprise Value | $8.72B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cytokinetics (CYTK) trades at $61.12, down 0.37% on the day, with a bearish technical signal from moving averages despite some oversold RSI readings. The company reported a net loss of $784.96 million on $88.04 million revenue in 2025, with a negative net income margin of -1,321.12% in 2026. Recent news highlights clinical progress for aficamten in hypertrophic cardiomyopathy and executive stock sales.
Wall Street maintains strong bullish sentiment with a 97.14% buy rating and $112.60 consensus price target, but high cash burn, persistent losses, and insider selling pose significant risks. The stock's outlook hinges on successful commercialization of its heart failure pipeline amid substantial financial and competitive pressures.
JPMorgan Ultra-Short Income ETF (JPST) trades at $50.27 with minimal daily movement (+0.04%). The ETF shows bearish technical signals with moving averages indicating selling pressure, though oscillators remain neutral. Recent institutional activity shows mixed sentiment with some firms reducing positions while others increased holdings. The fund continues its regular $0.17 dividend payments, maintaining income distribution consistency.
JPST faces headwinds from rising interest rate environment while benefiting from demand for ultra-short duration strategies. The ETF's active management approach has shown recent underperformance versus peers, creating both opportunity for yield-seeking investors and risk from competitive pressure. Market volatility continues to drive flows into cash-alternative strategies.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About JPMorgan Ultra Short Income ETF
JPST is an actively managed ETF that invests in short-term, investment-grade fixed income securities. It aims to provide current income and capital preservation while maintaining high liquidity.
Read more on JPST →
